Enanta Pharmaceuticals, Inc. (ENTA) scores 33 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $5.6, representing a 55% premium to fair value. Quantitative score: 51/100. Qualitative score: 20/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.